- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01251874
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer
Studie Overzicht
Toestand
Conditie
- BRCA1-genmutatie
- BRCA2-genmutatie
- Recidiverend mammacarcinoom
- Oestrogeenreceptor negatief
- Oestrogeenreceptor positief
- HER2/Neu-negatief
- Progesteronreceptor negatief
- Progesteronreceptor positief
- Triple-negatief borstcarcinoom
- Stadium IV Borstkanker AJCC v6 en v7
- Stadium IIIB Borstkanker AJCC v7
- Stadium IIIC Borstkanker AJCC v7
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To determine the recommended phase II dose of veliparib along with carboplatin on a 14-day and 21-day schedule in patients with Her2 negative metastatic breast cancer that are estrogen receptor (ER)/progesterone receptor(PR) negative or ER and/or PR positive with defects in Fanconi Anemia (FA) pathway repair genes.
II. To determine the safety and tolerability of combining veliparib on a 14-day and 21-day schedule with carboplatin in this patient population.
III. To determine the preliminary efficacy of this combination in this patient population.
SECONDARY OBJECTIVES:
I. To determine the pharmacodynamic endpoints of poly(ADP-ribose) polymerase (PARP) inhibition in the tumor by using, A) 3'-[F-18]fluoro-3'-deoxythymidine positron emission tomography (FLT-PET) of the target lesions, B) circulating tumor cells to detect the induction of the histone variant gamma H2AX, and C) peripheral blood mononuclear cells to assess poly ADP-Ribose (PAR) levels.
II. To determine biomarkers in the primary tumor that may predict antitumor responses to PARP inhibition such as breast cancer 1/2, early onset (BRCA)1/2 protein, Fanconi anemia, complementation group D2 (FANCD2) nuclear foci formation and expression of micro-ribonucleic acid (RNA) 155 (miR 155).
OUTLINE: This is a dose-escalation study of veliparib.
Patients receive carboplatin intravenously (IV) over 1 hour on day 1 and veliparib orally (PO) twice daily (BID) on days 1-7 or 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 12 weeks.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
New York
-
Bronx, New York, Verenigde Staten, 10461
- Montefiore Medical Center-Einstein Campus
-
Bronx, New York, Verenigde Staten, 10467
- Montefiore Medical Center - Moses Campus
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Patients must have histologically or cytologically proven metastatic or locally advanced inoperable breast cancer that fulfills one of the following two criteria:
- Triple-negative breast cancer
- ER and/or PR positive, HER2 negative if their tumors have been shown to be deficient for the FA pathway, based on FA triple stain immunofluorescence (FATSI) screening
HER negative with a known germline BRCA1/2 mutation
- Patients with ER- and/or PR-positive breast cancer will be consented to have their existing, or to be obtained, paraffin-embedded tumor tissue screened for FA deficiency
- No more than 3 prior chemotherapy regimens for metastatic disease will be allowed; any number of prior hormone therapies will be allowed; however, at least 4 weeks should have elapsed since prior chemotherapy (6 weeks for mitomycin C and nitrosoureas and 2 weeks for hormone therapy) or radiation therapy (2 weeks for limited field palliative radiation to the bone)
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Patients with treated brain metastases and life expectancy of greater than 3 months
- Patients with known Gilbert syndrome with abnormal unconjugated bilirubin will be eligible
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic acid transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- No prior therapy with veliparib for metastatic disease will be allowed
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
- Patients must be able to swallow pills
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients may not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib
- Known human immunodeficiency virus (HIV)-infected patients on protease inhibitors are ineligible; HIV-infected patients with adequate cluster of differentiation (CD)4 counts (> 500) and not on protease inhibitors are eligible
- Patients with active seizure or a history of seizures are not eligible
- Patients with uncontrolled central nervous system (CNS) metastasis are not eligible; patients with CNS metastases must be stable after therapy for > 3 months and off steroid treatment prior to study enrollment
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Treatment (veliparib, F 18 fluorothymidine, carboplatin)
Patients receive carboplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-7 or 1-14.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients may undergo fluorothymidine PET scan and peripheral blood cell and tumor tissue collection periodically for correlative studies.
|
Correlatieve studies
IV gegeven
Andere namen:
Correlatieve studies
Gegeven PO
Andere namen:
Correlatieve studies
Andere namen:
Correlatieve studies
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Incidence of adverse events to measure the safety and tolerability of this treatment combination
Tijdsspanne: Up to 12 weeks post-treatment
|
Number and severity of toxicity incidents will be tabulated.
Non-hematologic toxicities will be evaluated via the ordinal Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 standard toxicity grading.
Hematologic toxicity measures of thrombocytopenia, neutropenia and leukopenia will be assessed using continuous variables as the outcome measures (primarily nadir and percent change from baseline values) as well as categorization via CTCAE standard toxicity grading.
Frequency distributions and other descriptive measures will form the basis of the analysis of these variables.
|
Up to 12 weeks post-treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Clinical response (complete and partial response as well as stable and progressive disease)
Tijdsspanne: Up to 12 weeks post-treatment
|
Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease.
Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors guideline (version 1.1).
|
Up to 12 weeks post-treatment
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
PARP-1 activity
Tijdsspanne: Up to 5 years
|
Analysis will be descriptive and exploratory in nature.
Potential relationships and differences will be explored using graphical analyses and quantitative summaries of this marker.
|
Up to 5 years
|
Thymidine kinase uptake on 3'-[F-18]fluoro-3'-deoxythymidine positron emission tomography (FLT-PET) scans
Tijdsspanne: Up to 18 weeks (after course 3)
|
Analysis will be descriptive and exploratory in nature.
Potential relationships and differences will be explored using graphical analyses and quantitative summaries of this marker.
|
Up to 18 weeks (after course 3)
|
Circulating tumor cell markers
Tijdsspanne: Up to 5 years
|
Analysis will be descriptive and exploratory in nature.
Potential relationships and differences will be explored using graphical analyses and quantitative summaries of this marker.
|
Up to 5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Bhuvaneswari Ramaswamy, Ohio State University Comprehensive Cancer Center
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Huidziektes
- Neoplasmata per histologisch type
- Neoplasmata
- Neoplasmata per site
- Neoplasmata, glandulair en epitheel
- Borst ziekten
- Borstneoplasmata
- Carcinoom
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Antivirale middelen
- Enzymremmers
- Antineoplastische middelen
- Poly (ADP-ribose) polymeraseremmers
- Carboplatine
- Veliparib
- Alovudine
Andere studie-ID-nummers
- NCI-2011-02552 (Register-ID: CTRP (Clinical Trial Reporting Program))
- P30CA016058 (Subsidie/contract van de Amerikaanse NIH)
- UM1CA186712 (Subsidie/contract van de Amerikaanse NIH)
- U01CA076576 (Subsidie/contract van de Amerikaanse NIH)
- 8609 (Andere identificatie: CTEP)
- CDR0000688990
- OSU 10080
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op BRCA1-genmutatie
-
National Cancer Institute (NCI)VoltooidBRCA1-gen | BRCA2-genVerenigde Staten
-
Hamad Medical CorporationQatar UniversityVoltooid
-
Assiut UniversityNog niet aan het wervenGen amplificatie
-
Jiangsu Province Centers for Disease Control and...Bejing Vigoo Biological Co., LTDVoltooidSysteembiologie | Vroeg gen | EV71-vaccinChina
-
Wake Forest University Health SciencesNational Center for Complementary and Integrative Health (NCCIH); University... en andere medewerkersVoltooidVetzuur-gen-interactiesVerenigde Staten
-
Memorial Sloan Kettering Cancer CenterMemorial Health University Medical CenterVoltooid
-
Cervesi Hospital, Cattolica, ItalyWerving
-
Natera, Inc.VoltooidAandoeningen met één genVerenigde Staten
-
University of PennsylvaniaInovio PharmaceuticalsWerving
-
Weill Medical College of Cornell UniversityBasser Research Center for BRCAWerving
Klinische onderzoeken op Laboratorium Biomarker Analyse
-
Universidad Miguel Hernandez de ElcheInstitut Català de la Salut; Andaluz Health Service; Osakidetza; Servicio Madrileño... en andere medewerkersVoltooidBeroepsziektenSpanje
-
Vanderbilt University Medical Center4DMedicalVoltooid
-
Alcon ResearchVoltooid
-
McGill University Health Centre/Research Institute...Northwestern UniversityWerving
-
St. Antonius HospitalRoche DiagnosticsWervingKwaliteit van het leven | Postoperatieve complicaties | DoodNederland
-
Seoul National University HospitalOnbekendZiekte van Alzheimer | Milde cognitieve stoornisKorea, republiek van
-
University Medical Centre LjubljanaUniversity of LjubljanaActief, niet wervendHartstilstandSlovenië
-
Assiut UniversityNog niet aan het wervenSystemische lupus erythematosus
-
GAP Innovations, PBCVoltooidZiekte van Alzheimer | Milde cognitieve stoornis | Ziekte van Alzheimer, vroeg begin | Geheugenstoornissen | Geheugenstoornis | GeheugenverliesVerenigde Staten
-
Fundacio PuigvertNucleix Ltd.OnbekendUrologische neoplasmata | Urologische kankerSpanje